Abstract:Objectives: The purpose of this study was to retrospectively validate the prognostic value of revised 2018 FIGO stage IIIC Methods: This is a retrospective analysis of patients with cervical cancer in stage III of the revised 2018 FIGO Staging System who received standardized treatment from 2011 to 2014 at a cancer hospital. Multi-group comparisons were performed with the Kruskal-Wallis H test and chi-square test. Survival curves were calculated using the Kaplan-Meier method and the log-rank test. A Cox proportional hazard regression model was used for multivariable analysis. Results: A total of 418 women were included, 42(10.0%) stage IIIA, 120(28.7%) stage IIIB, 190(45.5%) stage IIIC1 and 66(15.8%) stage IIIC2, there was no significant difference in histological type, tumor differentiation, tumor size, type of radiotherapy, consolidation chemotherapy among the four groups (all, P > 0.05). The stage IIIC1 patients were younger compared to those with stage IIIA (P<0.001) and IIIB(P=0.01). On univariate survival analyses, the 2018 FIGO staging system was significantly associated with survival in stage III cervical cancer (P<0.001). Women with stage IIIC1 disease had significantly improved survival compared to those with stage IIIC2 (P<0.001); Survival of women with stage IIIC1 was similar compared to those IIIA (P=0.484) and IIIB (P=0.042) (5-year OS rates:54.1% for IIIC1, 43.3% for IIIA, 40.6% for IIIB, 23.1% for IIIC2). In a multivariable model, stage IIIC2 disease was independently associated with a two-fold increased mortality risk compared to stage IIIC1 (HR = 2.066, 95% CI: 1.438-2.969, P<0.001), 2.6-fold compared to stage IIIB (HR=2.606, 95% CI 1.752-3.877, P<0.001) or nearly 3-fold compared to stage IIIA (HR = 2.958, 95% CI 1.757-4.983, P<0.001). Survival of stage IIIC1 disease significantly differed based on T-stage (5-year OS rates:72.2% for T1 vs 54.1% for T2 vs 18.6% for T3, P<0.001). Patients with stage IIIC1 (T1) had better OS compared with stage IIIA (P=0.004) and IIIB (P<0.001); Patients with stage IIIC1(T3) had worse OS compared with stage IIIA and IIIB (both P=0.001). On multivariable analysis, T-stage remained an independent prognostic factor for survival in patients with 2018 FIGO stage IIIC1 (P<0.001). Stage IIIC1(T1) was independently associated with improved survival compared to stage IIIA (HR = 0.514, 95% CI 0.287-0.921, P=0.025) or stage IIIB disease (HR = 0.420, 95% CI 0.263-0.672, P<0.001). The best prognostic cut-off value of the number of metastatic pelvic lymph node (MPLNs) was 2 for stage IIIC1p(T1/T2a). Patients with >2 MPLNs had worse OS compared with those having <2 (5-year OS rates were 76% and 47.9%, respectively, P<0.001). Multivariate analyses demonstrated that the extent of MPLNs yield impact on OS(HR = 2.753, 95% CI 1.527-4.965, P=0.001). Conclusions: Patients with stage IIIC1 represent a heterogeneous population with a variable prognosis, using T stage and a cut-off value of 2 MPLNs could gain a better predict prognostic outcomes.

A Novel Risk Factor for Para-Aortic Lymph Node Recurrence After Definite Pelvic Radiotherapy in Stage IIIB Cervical Cancer

A novel predictor for the use of concurrent chemotherapy in early-stage cervical cancer with intermediate-risk factors.

The Prognostic Value of Regional Lymph Node Metastasis in Cervical Cancer Patients with Stage IIIC Receiving PET/CT Examination

Clinical Outcomes and Prognostic Factors in Stage III C Cervical Cancer Patients Treated with Radical Radiotherapy or Radiochemotherapy

Predictive Factors of Para-Aortic Lymph Nodes Metastasis in Cervical Cancer Patients: a Retrospective Analysis Based on 723 Para-Aortic Lymphadenectomy Cases.

A Novel Scoring System Predicting Survival Benefits of Palliative Primary Tumor Resection for Patients with Unresectable Metastatic Colorectal Cancer: A Retrospective Cohort Study Protocol.

The Value of Lymph Node Ratio in the Prediction of Rectal Cancer Patient Survival after Preoperative Chemoradiotherapy.

Which Patients with Cervical Cancer Could Benefit from Prophylactic Extended-Field Irradiation?

Para-Aortic Lymph Node Dissection for Patients with Node-Negative Cervical Squamous Cell Carcinoma: A Retrospective Cohort Study

Adjuvant Radiation Field Extent and Sites of Failure in Node Positive Endometrioid Endometrial Cancer

Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer

Preoperative controlling nutritional status (CONUT) score is a prognostic factor for early-stage cervical cancer patients with high-risk factors

A Scoring System to Select the Candidates for Adjuvant Chemotherapy Alone in High-Risk Early-Stage Cervical Cancer Patients With Pelvic Lymph Node Metastases After Surgery

Predictive Significance of Lymphocyte Level and Neutrophil‐to‐lymphocyte Ratio Values During Radiotherapy in Cervical Cancer Treatment

Radiotherapy can improve overall survival in patients with lymph-node positive, high-grade neuroendocrine cervical cancer: construction of two prognostic nomograms to predict treatment outcome

Assessment of Peripheral Platelet to Lymphocyte Ratio and Prognostic Nutritional Index in the Efficacy and Prognosis of Radiotherapy for Cervical Cancer.

Validation of the prognostic value of the 2018 FIGO stage IIIC in patients with cervical cancer

Long-term survival in patients with para-aortic metastatic cervical cancer receiving simultaneous integrated boost chemoradiation to positive lymph nodes: a single-center experience

Identifying High Risk Factors in Locally Advanced Rectal Cancer Patients with Ypt0-2n0 after Preoperative Chemoradiation

Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis

The prognostic value of radiological and pathological lymph node status in patients with cervical cancer who underwent neoadjuvant chemotherapy and followed hysterectomy